Company news

Dare Bioscience, Inc. news in 2022

Dare Bioscience, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Daré Bioscience Announces New Development Program, DARE-PDM1, as a Potential First-in-Category Treatment for Primary Dysmenorrhea

December 11, 2022

Daré Bioscience Announces Grant to Develop Novel Hydrogel Formulation for Delivery of Live Biotherapeutics to Support Vaginal Health

November 14, 2022

Daré Bioscience Announces Positive Topline Results from DARE-VVA1 Phase 1/2 Clinical Study

November 13, 2022

Daré Bioscience Reports Third Quarter 2022 Financial Results and Provides a Company Update

November 9, 2022

Daré Bioscience Announces Subject Screening for Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder Complete

October 31, 2022

Daré Bioscience Announces Positive Efficacy Results from the DARE-HRT1 Phase 1 / 2 Study

October 16, 2022

Daré Bioscience Announces IDE Approval for a Single Arm, Open-Label Pivotal Contraceptive Efficacy Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive

October 9, 2022

Daré Bioscience Announces Interim Analysis of Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder

August 28, 2022

Daré Bioscience, Inc. Announces Global Licensing Rights to the Novel Antimicrobial Glycerol Monolaurate for Vaginal Health

August 23, 2022

Daré Bioscience Reports Second Quarter 2022 Financial Results and Provides a Company Update

August 8, 2022

Daré Bioscience to Host Second Quarter 2022 Financial Results and Company Update Conference Call and Webcast on August 9, 2022

August 1, 2022

Daré Bioscience Announces Closing of Global License Agreement with Organon to Commercialize XACIATO™ (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis

June 29, 2022

Daré Bioscience Announces Partial Adjournment of Annual Meeting of Stockholders to July 14, 2022

June 23, 2022

Daré Bioscience to Participate in the 2022 BIO International Convention

June 5, 2022

Daré Bioscience Reports First Quarter 2022 Financial Results and Provides a Company Update

May 11, 2022

Daré Bioscience Announces NIH Grant Award

May 10, 2022

Daré Bioscience to Host First Quarter 2022 Financial Results and Company Update Conference Call and Webcast on May 12, 2022

May 4, 2022

Daré Bioscience Initiates Phase 1/2 Clinical Study of DARE-HRT1

April 11, 2022

Daré Bioscience Reports Full-Year 2021 Financial Results and Provides a Company Update

March 30, 2022

Calls in 2022

Decks in 2022